Dr. Zhiyong He 何志勇
Chief Physician
Department of Thoracic Medical Oncology, Fujian Cancer Hospital, Fuzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of thoracic malignancies, including lung cancer, esophageal cancer, thymic malignancies, and pleural mesothelioma. Specializes in comprehensive medical management of lung cancer using chemotherapy, targeted therapy, and immunotherapy.
Dr. He is a Chief Physician in the Department of Thoracic Medical Oncology at Fujian Cancer Hospital. Dr. He served as a Senior Visiting Scholar at the City of Hope National Medical Center. Dr. He has participated in multiple domestic and international multicenter clinical trials and translational studies on lung and esophageal cancers.
Name order: in Chinese the family name comes first (He Zhiyong). Papers usually list the name as Zhiyong He or He Z.
Selected publications
29 papers on PubMed matched by name and affiliation; 6 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Immunol, 2025 (senior author): Efficacy and safety of SMET12 in combination with toripalimab and chemotherapy in advanced non-small-cell lung cancer patients tested positive for EGFR protein who are treatment-naïve or harbor acquired resistance to standard therapy: a phase 2, multi-cohort clinical trial. PubMed 41583476
- Oncol Lett, 2024 (senior author): Efficacy analysis of immunotherapy‑based combinations for patients with EGFR‑mutant advanced non‑small cell lung cancer after TKI failure. PubMed 39233818
- Anticancer Agents Med Chem, 2023 (senior author): Efficacy of Osimertinib Continuation Plus Metronomic Oral Vinorelbine for EGFRmutant Advanced NSCLC Beyond Limited Progression on Osimertinib. PubMed 37534792
- J Inflamm Res, 2021 (senior author): Efficacy and Safety of First-Generation EGFR-TKIs Combined with Chemotherapy for Treatment-Naïve Advanced Non-Small-Cell Lung Cancer Patients Harboring Sensitive EGFR Mutations: A Single-Center, Open-Label, Single-Arm, Phase II Clinical Trial. PubMed 34168480
- Transl Cancer Res, 2020 (first author): Spred-3 mutation and Ras/Raf/MAPK activation confer acquired resistance to EGFR tyrosine kinase inhibitor in an EGFR mutated NSCLC cell line. PubMed 35117614
- Cancer Manag Res, 2019 (first author): Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell lung cancer with brain metastases: a retrospective cohort study. PubMed 30936745
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion